Top

World Journal of Surgery

Published in:

01-10-2010

Reply: Apples, Oranges, Metastatic Colorectal Cancer: has the Time for a Randomized Trial Come?

Authors: A. P. Stillwell, Y.-H. Ho, P. G. Buettner

Published in: World Journal of Surgery | Issue 10/2010

Excerpt

Dear Sir, …

Bajwa A, Blunt N, Vyas S et al (2009) Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol 35:164–167PubMed

Galizia G, Lieto E, Orditura M et al (2008) First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg 143:352–358CrossRefPubMed

Tebbutt NC, Norman AR, Cunningham D et al (2003) Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 52:568–573CrossRefPubMed

Van Hooft JE, Fockens P, Marinelli AW et al (2008) Early closure of a multicenter randomized clinical trial of endoscopic stenting versus surgery for stage IV left-sided colorectal cancer. Endoscopy 40:184–191CrossRefPubMed

Poultsides GA, Servais EL, Saltz LB et al (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27:3379–3384CrossRefPubMed

Benoist S, Pautrat K, Mitry E et al (2005) Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 92:1155–1160CrossRefPubMed

Michel P, Roque I, Di Fiore F et al (2004) Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol 28:434–437CrossRefPubMed

Hapani S, Chu D, Wu S et al (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559–568CrossRefPubMed

Sugrue M, Kozloff M, Hainsworth J et al (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24:3535CrossRef

10.

Deshaies I, Malka D, Soria JC, Massard C, Bahleda R, Elias D (2010) Antiangiogenic agents and late anastomotic complications. J Surg Oncol 101:180–183PubMed

Title: Reply: Apples, Oranges, Metastatic Colorectal Cancer: has the Time for a Randomized Trial Come?
Authors: A. P. Stillwell
Y.-H. Ho
P. G. Buettner
Publication date: 01-10-2010
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 10/2010
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-010-0643-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reply: Apples, Oranges, Metastatic Colorectal Cancer: has the Time for a Randomized Trial Come?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2010

Video-Assisted Bilateral Neck Exploration in Patients with Primary Hyperparathyroidism and Failed Localization Studies

Pancreaticojejunal Bridge-Anastomosis: A Novel Option for Surgeon to Preserve Pancreatic Body and Tail in Urgent Reoperation for Intra-abdominal Massive Hemorrhage after Pancreaticoduodenectomy

Increasing Donor Body Weight to Prevent Small-for-Size Syndrome in Living Donor Liver Transplantation

Response to “Letter to the Editor: Cost Effective Surgery for Cleft Lip and Palate in the Developing World”

Fatal Acute Pancreatitis Occurring Outside of the Hospital: Clinical and Social Characteristics

Recurrent Laryngeal Nerve Monitoring During Esophagectomy and Mediastinal Lymph Node Dissection